Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by stockman6767on Jul 11, 2017 9:49am
215 Views
Post# 26454699

RE:RE:RE:RE:RE:RE:RE:so what happened to $10 like all the sillies

RE:RE:RE:RE:RE:RE:RE:so what happened to $10 like all the sillies This mornings news indicates to me that the delay CIBC was concerned about, may not be as bad as they thought or may not happen at all. They wrote: "after RyplazymTM receives its expected accelerated approval in the fourth quarter of 2017." So we still seem to be on track for a Q4 approval. Also  contrary to prior speculation by some, we seem to defintely be in the running for the PV. "Prometic has provided further data to the FDA to support its claims that the serious and life-threatening clinical manifestations associated with congenital plasminogen deficiency occurs predominantly in pediatric patients, as required to qualify for a rare pediatric disease designation."
And we are also moving forward with EMA and Health Canada. 

I would say that this is a very positive PR. CIBC should have waited before they dropped their target so hugely. Now they will look very stupid and backstabbing (selling short just before their release..
Bullboard Posts